Physicians today find themselves in a rapidly changing health care environment.In this new era of practice aggregation and ...

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a press release.With this approval, Zevaskyn (prademagene zamikeracel, Abeona) ...